Takeda Raises Full-Year Outlook On Strong Mainstays
Exec Reshuffle, TAK-721 Dropped
Executive Summary
Japan's largest pharma firm logs what was generally viewed by analysts as a solid fiscal third quarter, driven by growth for its portfolio of global products, leading to raised guidance for the full year despite one pipeline setback. There will also be multiple C-suite reshuffles come 1 April.
You may also be interested in...
Keeping Track: US FDA Clears Vtama, But Not Bimekizumab Or Ycanth; Tibsovo Takes RTOR To Frontline AML Setting
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Sanofi Closes In On A Pair Of Approval Firsts
The French major has secured a fourth approval, in eosinophilic esophagitis, for Dupixent, while the EMA is set to make Sanofi's enzyme replacement therapy, Xenpozyme, the first drug approved in Europe for acid sphingomyelinase deficiency.
Protagonist Weaves Positive Story From Mixed Phase II Data In Ulcerative Colitis
The company is pushing ahead into Phase III development with the lower dose of an oral drug for ulcerative colitis, even though a Phase II study missed the primary endpoint.